Supporting a better clinical management of neurocysticercosis
Epilepsy is one of the most common clinical signs in patients with neurocysticercosis (NCC). WHO recognizes that epilepsy is one of the most common chronic neurological diseases, and that people with epilepsy frequently suffer stigmatization and discrimination. WHO urges the Member States to support the establishment and implementation of strategies for the management of epilepsy, and promote actions to prevent the causes of epilepsy (Resolution WHA 68.20 of 2015).
In this context, clinical management of patients with NCC to prevent and manage epilepsy is an essential component, and the countries are requesting clear guidance to improve case detection and management of neurocysticercosis.
WHO has conducted a landscape analysis on the management of neurocysticercosis with an emphasis on low-and middle income countries, has completed a systematic review on the topic, and is now in the last steps of completing and finalising the diagnosis and treatment guidelines for Taenia solium NCC.
